Not medical advice. Hexarelin is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
Hexarelin is listed in our catalogue under “HGH / Somatropin.” In scientific publications it is discussed in technical language; this page translates the general themes into everyday wording while staying faithful to research-only framing.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
Hexarelin (Examorelin), potent hexapeptide GHS-R1a agonist producing synergistic GH release with GHRH and cardioprotective CD36 receptor activation.
Peer-reviewed literature typically discusses Hexarelin in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Growth-hormone axis peptides are researched for how they signal through the GH/IGF pathway in animals and cells. Studies focus on endocrine biology and metabolism, not on prescribing or outcomes in people.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 100–200 mcg subcutaneously · 1–3 times daily · GH Tmax ≈ 30 min; GH returns to baseline within 240 min with t½ ≈ 55 min; SC t½ ≈ 1–2 h; detectable up to 8 h post-administration. GH plateau at 140 mU/L at 1.0 mcg/kg dose. Partial reversible tolerance develops with chronic use (50–75% efficacy reduction over weeks–months).
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
Hexarelin is a more potent version of the GHRP-6 scaffold with two non-natural amino-acid substitutions (D-2-methyltryptophan and D-phenylalanine) that improve stability and GH-releasing potency. It also has clearer CD36-mediated cardiac effects than the simpler GHRP-6.
CD36 is a scavenger receptor that handles fatty acid uptake and calcium channel modulation in cardiomyocytes. Hexarelin activation of cardiac CD36 improves calcium handling and has been proposed as a mechanism for its cardioprotective effects in post-ischemic injury models.
Yes, hexarelin produces some cortisol and prolactin elevation at higher doses, more than ipamorelin but generally less than GHRP-6. Low-dose protocols minimise those secondary effects while preserving GH release.
Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. The non-natural amino acid substitutions give it better shelf stability than simpler GHRPs.
Both are ghrelin-receptor (GHSR) agonists that release growth hormone, but hexarelin is the more potent GH releaser and adds CD36-mediated cardiac activity, while ipamorelin is the cleaner, more selective option with minimal cortisol, prolactin or appetite effect. Hexarelin also desensitises faster with continuous exposure. See our Hexarelin vs Ipamorelin research comparison for the full mechanism breakdown.
Research protocols describe low-microgram subcutaneous amounts, often split through the day, with lower amounts used to limit cortisol/prolactin rise and receptor desensitisation. New-U publishes this as descriptive research context only - it is not a dosing instruction, and hexarelin is supplied strictly for laboratory research, not human use.
Beyond growth-hormone release, hexarelin is studied for CD36-mediated cardioprotective effects in post-ischaemic injury models and for calcium-handling in cardiomyocytes - an angle the simpler GHRPs lack. These are preclinical research findings; New-U makes no therapeutic claims and sells hexarelin for research use only.
Yes - continuous high-amount exposure downregulates the ghrelin receptor and blunts the GH response faster than with ipamorelin, which is why research protocols favour lower amounts and cycling. Reported for research context only, not a human-use protocol.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Other compounds researchers often read about alongside Hexarelin.
Primary literature and registries for Hexarelin, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: Examorelin, EP-23905, MF-6003, Hexarelin Acetate, His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2